ARCHIVES

Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.

April 30, 2004

Five Center Core Grants Renewed

February 2, 1979

Leukemia Biology Study Needed To Improve Results, Pinkel Says In Karnfsky Lecture

April 7, 1978

ORI Instructs NSAB to Prepare for Investigation

April 19, 1996

NCI, HCFA Negotiate Demonstration Project as Congress, Advocates Exert Pressure

September 27, 1996